89792-11-0 Usage
Uses
Used in Medicinal Chemistry:
4H-Pyrrolo[2,3-d]pyrimidin-4-one, 1,7-dihydro-2-methyl(9CI) is used as a compound with potential biological activities for the development of new drugs. Its unique structure may contribute to its interaction with biological targets, making it a promising candidate for further research and development in the pharmaceutical industry.
Used in Drug Development:
In the field of drug development, 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 1,7-dihydro-2-methyl(9CI) is utilized as a starting material or a building block for the synthesis of more complex molecules with therapeutic potential. Its heterocyclic nature and the presence of a pyrimidine core make it a valuable component in the design of novel drugs targeting various diseases and conditions.
Research on the synthesis and properties of 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 1,7-dihydro-2-methyl(9CI) can provide valuable insights into its potential uses and applications, contributing to the advancement of medicinal chemistry and drug development.
Check Digit Verification of cas no
The CAS Registry Mumber 89792-11-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,9,7,9 and 2 respectively; the second part has 2 digits, 1 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 89792-11:
(7*8)+(6*9)+(5*7)+(4*9)+(3*2)+(2*1)+(1*1)=190
190 % 10 = 0
So 89792-11-0 is a valid CAS Registry Number.
89792-11-0Relevant academic research and scientific papers
FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREAMENT OF INFLAMMATION
-
Page/Page column 71; 72, (2009/03/07)
Compounds are provided that act as potent antagonists of the CCR2 receptor. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2- mediated diseases and as controls in assays for the identification of CCR2 antagonists. A compound of the formula (I) or a salt thereof: where: R1 and R2 are each independently hydrogen, halogen, C1-8alkyl, -CN. or C1-8 haloalkyl, provided that at least one of R11or R2 is other than hydrogen; each R3 is independently hydrogen; R4 is hydrogen; R5 is halogen or C1-8 alkyl; R6 is hydrogen; X1 is CR7, N or NO; X2 and X4 are N or NO; X3 is CR7; X6 and X7 are each independently selected from CR7, N, and NO; each R7 is independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C2-8 alkyl, substituted or unsubstituted C2-8 alkeπyl, substituted or unsubstituted C2-8 alkynyl, -CN. =O, -NO2, -OR6, -OC(O)R8, -CO2R8, -C(O)R8, -C(O)NR0R8, -OC(O)NR9R8, -NR10C(O)R8, -NR10C(O)NR9R8, -NR9R8, -NR10CO2R8, -SR8, -S(O)R8, -S(O)2R8, -S(O)2NR9R8, -NR10S(O)2R8, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl and substituted or unsubstituted 3- to 10-membered heterocyclyl;
